Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAILBLAZER: SB-728-T for HIV
NCT03666871Phase 2Completed
- Sponsor
- University of Cincinnati
- Start
- Jun 2019
- Primary completion
- Jan 2024
- Modality
- Gene Silencing, Zinc Finger Nucleases, Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of SB-728-T in human immunodeficiency virus infection (HIV), sponsored by University of Cincinnati. Started Jun 2019; status: completed.
02
Drugs
SB-728-T
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03666871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666871.